» Articles » PMID: 23049873

Molecular Characteristics and Metastasis Predictor Genes of Triple-negative Breast Cancer: a Clinical Study of Triple-negative Breast Carcinomas

Overview
Journal PLoS One
Date 2012 Oct 11
PMID 23049873
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Triple-negative breast cancer is a subtype of breast cancer with aggressive tumor behavior and distinct disease etiology. Due to the lack of an effective targeted medicine, treatment options for triple-negative breast cancer are few and recurrence rates are high. Although various multi-gene prognostic markers have been proposed for the prediction of breast cancer outcome, most of them were proven clinically useful only for estrogen receptor-positive breast cancers. Reliable identification of triple-negative patients with a favorable prognosis is not yet possible.

Methodology/principal Findings: Clinicopathological information and microarray data from 157 invasive breast carcinomas were collected at National Taiwan University Hospital from 1995 to 2008. Gene expression data of 51 triple-negative and 106 luminal breast cancers were generated by oligonucleotide microarrays. Hierarchical clustering analysis revealed that the majority (94%) of triple-negative breast cancers were tightly clustered together carrying strong basal-like characteristics. A 45-gene prognostic signature giving 98% predictive accuracy in distant recurrence of our triple-negative patients was determined using the receiver operating characteristic analysis and leave-one-out cross validation. External validation of the prognostic signature in an independent microarray dataset of 59 early-stage triple-negative patients also obtained statistical significance (hazard ratio 2.29, 95% confidence interval (CI) 1.04-5.06, Cox P=0.04), outperforming five other published breast cancer prognostic signatures. The 45-gene signature identified in this study revealed that TGF-β signaling of immune/inflammatory regulation may play an important role in distant metastatic invasion of triple-negative breast cancer.

Conclusions/significance: Gene expression data and recurrence information of triple-negative breast cancer were collected and analyzed in this study. A novel set of 45-gene signature was found to be statistically predictive in disease recurrence of triple-negative breast cancer. The 45-gene signature, if further validated, may be a clinically useful tool in risk assessment of distant recurrence for early-stage triple-negative patients.

Citing Articles

DrugSim2DR: systematic prediction of drug functional similarities in the context of specific disease for drug repurposing.

Wu J, Li J, He Y, Huang J, Zhao X, Pan B Gigascience. 2023; 12.

PMID: 38116825 PMC: 10729734. DOI: 10.1093/gigascience/giad104.


Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.

Wilkerson A, Parthasarathy P, Stabellini N, Mitchell C, Pavicic Jr P, Fu P Clin Cancer Res. 2023; 30(1):82-93.

PMID: 37882661 PMC: 10767305. DOI: 10.1158/1078-0432.CCR-23-1349.


E-Selectin Targeted Gold Nanoshells to Inhibit Breast Cancer Cell Binding to Lung Endothelial Cells.

Fereshteh Z, Dang M, Wenck C, Day E, Slater J ACS Appl Nano Mater. 2023; 6(2):1315-1324.

PMID: 37789828 PMC: 10544796. DOI: 10.1021/acsanm.2c04967.


Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI.

Liu C, Zhang Y, Gao X, Wang G BMC Biol. 2023; 21(1):159.

PMID: 37468850 PMC: 10354926. DOI: 10.1186/s12915-023-01658-3.


Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer.

Couto J, Vulin M, Jehanno C, Coissieux M, Hamelin B, Schmidt A EMBO J. 2023; 42(13):e112559.

PMID: 37259596 PMC: 10308372. DOI: 10.15252/embj.2022112559.


References
1.
Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

2.
Rakha E, Tan D, Foulkes W, Ellis I, Tutt A, Nielsen T . Are triple-negative tumours and basal-like breast cancer synonymous?. Breast Cancer Res. 2008; 9(6):404. PMC: 2246182. DOI: 10.1186/bcr1827. View

3.
Kreike B, Van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H . Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 2007; 9(5):R65. PMC: 2242660. DOI: 10.1186/bcr1771. View

4.
J van t Veer L, Dai H, van de Vijver M, He Y, Hart A, Mao M . Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002; 415(6871):530-6. DOI: 10.1038/415530a. View

5.
Smola M, Estelberger W, Reiter M, Schauenstein K, SCHAUENSTEIN E . Sigma S, a measure of reactive sulfur groups of immunoglobulin G, is a sensitive tumor marker discriminating different stages of breast cancer. Cancer. 1991; 68(5):1026-30. DOI: 10.1002/1097-0142(19910901)68:5<1026::aid-cncr2820680520>3.0.co;2-h. View